In a recent experimental study, PARP inhibitor modulated cancer-associated immunosuppression by upregulating programmed death ligand 1 (PD-L1) in breast cancer cell lines suggesting that blockade of PD-L1 could restore their sensitivity to the PARP inhibitor. Here, CD274 is linked to breast carcinoma.